🧾 What This Document Is

This is a standard regulatory filing, called a 6-K, from the biotech company Genmab. Its sole purpose is to publicly disclose stock transactions made by its top executives. Think of it as a required transparency report so investors know what the company's leaders are doing with their own company shares.

👉 Why it matters: It's a legal requirement under European market abuse rules. This ensures no one can trade on secret information without the public knowing.

🏢 What The Company Does

In simple terms, Genmab is a cutting-edge biotech company that creates advanced antibody-based medicines, primarily to fight cancer. They've been around for over 25 years and have developed a technology platform that has led to eight approved drugs. They are known for complex, next-generation therapies.

👉 Why it matters: This context is key because the executives receiving these shares are the leaders of a major, innovative pharmaceutical firm. Their compensation is tied directly to the company's stock performance.

📦 The Transactions — Who Got What

The filing details one specific type of transaction for six top executives: the vesting of Restricted Stock Units (RSUs). This isn't a cash purchase or a sale. It's the executives earning shares that were promised to them as part of their pay package, which are now "vesting" (becoming their property). All transactions happened on April 1, 2026.

Here’s a breakdown of the executives and the shares they acquired through this vesting:

Name	Title	Shares Acquired	Price per Share
Jan van de Winkel	President & CEO	8,525	DKK 1,758.50
Anthony Pagano	EVP & Chief Financial Officer	4,206	DKK 1,758.50
Martine van Vugt	EVP & Chief Strategy Officer	439	DKK 1,758.50
Tahamtan Ahmadi	EVP & Chief Medical Officer	5,186	DKK 1,758.50
Christopher Cozic	EVP & Chief People Officer	2,825	DKK 1,758.50
Judith Klimovsky	EVP & Chief Development Officer	4,744	DKK 1,758.50

👉 Key takeaway: The CEO received the largest grant, which is typical. All shares were valued at the same price (DKK 1,758.50), which was the market price at vesting. This was an internal transfer, not an open-market trade ("Outside the market").

💡 Why This Matters — The Bigger Picture

This filing is routine, but it reveals important things about the company:

• 👍 Strength: It shows that executive compensation is aligned with shareholders. Leaders own stock and their wealth is tied to the company's success. This incentivizes them to grow the company's value.
• ⚠️ Not a Red Flag: This is not insiders selling their stock. They are simply receiving part of their earned compensation. It's a normal, positive event in the corporate lifecycle. Selling would be a more significant signal to watch.

🔮 What's Next

This filing itself doesn't signal a strategic shift. However, the executives now hold more shares. Their future actions (holding, selling, or buying more) will be disclosed in future filings and will be more indicative of their confidence in the company's prospects.

🧠 The Analogy

Imagine a sports team's star players have bonuses built into their contracts that are paid in team stock. This filing is just the team announcing, "On this date, the players earned and received their contractual stock bonuses." It's a scheduled part of their pay, not a sign they are betting on the team or planning to leave.

📇 Key Contacts & People

The filing lists the following Genmab leadership and corporate contacts:

• Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
  • T: +1 609 524 0065; E: [email protected]
• Andrew Carlsen, Vice President, Head of Investor Relations
  • T: +45 3377 9558; E: [email protected]

Company Address: Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark Tel: +45 7020 2728 www.genmab.com

🧩 Final Takeaway

This is a transparent, legally required report showing Genmab's top executives earned shares as part of their compensation. It's a sign of aligned incentives, not a market signal. The real insights into company direction will come from their future trading activity and, more importantly, from their clinical trial and financial results announcements.